Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188


DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding.

Schoofs T, Rohde C, Hebestreit K, Klein HU, Göllner S, Schulze I, Lerdrup M, Dietrich N, Agrawal-Singh S, Witten A, Stoll M, Lengfelder E, Hofmann WK, Schlenke P, Büchner T, Hansen K, Berdel WE, Rosenbauer F, Dugas M, Müller-Tidow C.

Blood. 2013 Jan 3;121(1):178-87. doi: 10.1182/blood-2012-08-448860. Epub 2012 Nov 14.


Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.

Zheng X, Seshire A, Rüster B, Bug G, Beissert T, Puccetti E, Hoelzer D, Henschler R, Ruthardt M.

Haematologica. 2007 Mar;92(3):323-31.


Understanding the molecular pathogenesis of acute promyelocytic leukemia.

Lo-Coco F, Hasan SK.

Best Pract Res Clin Haematol. 2014 Mar;27(1):3-9. doi: 10.1016/j.beha.2014.04.006. Epub 2014 Apr 13. Review.


Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase.

Benedetti L, Grignani F, Scicchitano BM, Jetten AM, Diverio D, Lo Coco F, Avvisati G, Gambacorti-Passerini C, Adamo S, Levin AA, Pelicci PG, Nervi C.

Blood. 1996 Mar 1;87(5):1939-50.


Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.

Rusiniak ME, Yu M, Ross DT, Tolhurst EC, Slack JL.

Cancer Res. 2000 Apr 1;60(7):1824-9.


Two critical hits for promyelocytic leukemia.

He LZ, Bhaumik M, Tribioli C, Rego EM, Ivins S, Zelent A, Pandolfi PP.

Mol Cell. 2000 Nov;6(5):1131-41.


The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.

Jing Y.

Leuk Lymphoma. 2004 Apr;45(4):639-48. Review.


PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors.

Wojiski S, Guibal FC, Kindler T, Lee BH, Jesneck JL, Fabian A, Tenen DG, Gilliland DG.

Leukemia. 2009 Aug;23(8):1462-71. doi: 10.1038/leu.2009.63. Epub 2009 Mar 26.


Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell.

Puccetti E, Ruthardt M.

Leukemia. 2004 Jul;18(7):1169-75. Review.


PRAM-1 is a novel adaptor protein regulated by retinoic acid (RA) and promyelocytic leukemia (PML)-RA receptor alpha in acute promyelocytic leukemia cells.

Moog-Lutz C, Peterson EJ, Lutz PG, Eliason S, Cavé-Riant F, Singer A, Di Gioia Y, Dmowski S, Kamens J, Cayre YE, Koretzky G.

J Biol Chem. 2001 Jun 22;276(25):22375-81. Epub 2001 Apr 11.


Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response.

Grignani F, Gelmetti V, Fanelli M, Rogaia D, De Matteis S, Ferrara FF, Bonci D, Grignani F, Nervi C, Pelicci PG.

Oncogene. 1999 Nov 4;18(46):6313-21.


High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression.

Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, Zimonjic DB, Popescu NC, DiPersio JF, Ley TJ.

Blood. 2003 Sep 1;102(5):1857-65. Epub 2003 May 15.


Retinoic acid receptors: involvement in acute promyelocytic leukemia.

Agadir A, Cornic M, Gourmel B, Lefebvre P, Degos L, Chomienne C.

Cell Mol Biol (Noisy-le-grand). 1994 May;40(3):263-74. Review.


A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation.

Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr.

Blood. 1997 Jun 15;89(12):4282-9.

Supplemental Content

Support Center